HLA-C and cancer: This TCR recognises cancer regardless of tissue origin, and as MR1 is monomorphic in the population, this TCR has potential to be used as an “off-the-shelf” TCR that can be used in many patients without the caveat of MHC-restriction, analogous to CAR-T-cells.